Pediatric labeling milestone
FDA's approval of new labeling for Novartis' seizure therapy Trileptal addressing its use in children and teenagers marks the 100th product to add pediatric information to its label since the implementation of the FDA Modernization Act in 1997, the agency announces Dec. 19. "This is a highly gratifying achievement for our most precious patients, their parents, and their physicians," Acting FDA Commissioner Andrew von Eschenbach said. Since FDAMA was enacted, manufacturers have conducted more than 250 pediatric studies for 125 products compared to only 11 such studies in the seven years prior to the legislation. FDAMA, along with the 2002 Best Pharmaceuticals for Children Act, provide sponsors incentives for conducting pediatric trials (1"The Pink Sheet" May 14, 2001, p. 21)...
You may also be interested in...
Negotiations for pediatric labeling changes would be limited to six months under a proposed bill to reauthorize the pediatric exclusivity provisions.
Amneal is close to a filed pipeline of three biosimilar products in the US, while furthering ambitions in the complex generics and 505(b)(2) space, management told the virtual J.P. Morgan Healthcare Conference.
Zydus Cadila is to begin testing a three-dose recombinant DNA vaccine candidate in Phase III Indian trials, which might enter late-stage development ahead of Inovio and AnGes. The company promised to provide 100-150 million doses by end of 2021 at the J.P. Morgan Conference, though adherence could be a roadblock.